scholarly journals Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer

2021 ◽  
Vol 8 ◽  
Author(s):  
Karim Amrane ◽  
Luca Campedel ◽  
Coline Le Meur ◽  
Ronan Abgral ◽  
Dris Kharroubi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Case Report ◽  
Fdg Pet ◽  
Kinase Inhibitor ◽  
Metabolic Response ◽  
Complete Metabolic Response ◽  
Anaplastic Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct

Crizotinib is a tyrosine kinase inhibitor (TKI) indicated in first-line treatment of rearranged c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) metastatic non-small-cell lung cancer (NSCLC). However, the common response reported after treatment is partial and few complete responses have been reported in PROFILE studies with computed tomography (CT) evaluation. To date, only one case report of complete metabolic response on 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography-computed tomography (18F-FDG-PET/CT) was published, reporting on a patient with ROS1 rearranged NSCLC. We highlighted the 18F-FDG-PET/CT useful approach for therapeutic assessment of TKI in metastatic mutated NSCLC reporting two complete metabolic responses in patients treated with crizotinib for a rearranged ROS1 and a metastatic ALK NSCLC.

Necrosis, as Identified on Pre-Radiotherapy 18F-FDG PET/CT, is a Predictor for Complete Metabolic Response in Patients with Non-Small Cell Lung Cancer.

2021 ◽  
Author(s):  
Gülnihan Eren ◽  
Osman Kupik
Keyword(s):  
Lung Cancer ◽  
Regression Analysis ◽  
Fdg Pet ◽  
Tumor Volume ◽  
Metabolic Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Complete Metabolic Response ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Purpose: To investigate necrosis on pre-radiotherapy (RT) 18F-FDG PET/CT (PETNECROSİS) is a predictor for complete metabolic response (CMR) in patients with non-small cell lung cancer (NSCLC).Methods: We studied patients with inoperable stage I-III NSCLC who underwent pre- and post-radiotherapy 18F-FDG PET/CT. The relationship between CMR and PETNECROSIS, SUVmax, gross tumor volume calculated with 18F-FDG PET/CT (GTVPET-CT), tumor size, histology, metabolic tumor volume (MTV), and RT dose was assessed using logistic regression analysis. To evaluate necrosis on 18F FDG PET/CT, we drew a region of interest (ROI) in the area showing visually very low/or no fluorodeoxyglucose (FDG) uptake on PET images. If the SUVmax was lower than the blood pool SUVmax and showed significantly lower attenuation [10 to 30 Hounsfield Units (HU)] from the surrounding tissue on non-intravenous contrast-enhanced low dose correlative CT, we defined it as necrotic (PETNECROSİS).Results: Fifty-three patients were included in the study. The mean age was 68.1±9.8 years. Twenty-one patients had adenocarcinoma, 32 had squamous cell carcinoma. All parameters were independent of histologic status. Multivariate logistic regression analysis showed that, SUVmax ≤11.6vs>11.6 (p=0.003, OR:7.670, 95CI%:2.013-29.231) and PETNECROSİS absence/presence were independent predictors for CMR (p=0.028, OR:6.704, 95CI%1.214-30.394).Conclusion: The necrosis on 18F FDG PET/CT and SUVmax>11.6 could be an imaging marker for the complete metabolic response after chemoradiotherapy or RT alone in patients with NSCLC.

scholarly journals Comparison of Tumor Target Volume on Four-Dimensional Computed Tomography and 18F-FDG PET/CT in Lung Cancer

2018 ◽  
Vol 36 (3) ◽  
pp. 223
Author(s):  
Keeratikarn Boonyawan ◽  
Sasipilai Naivikul ◽  
Putipun Puataweepong ◽  
Wichana Chamroonrat ◽  
Thiti Swangsilpa ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Volume Change ◽  
Fdg Pet ◽  
Gross Tumor Volume ◽  
Tumor Volume ◽  
Pet Ct ◽  
Centroid Shift ◽  
18F Fdg ◽  
Fdg Pet Ct

Objective: The correlation between 18F-fluorodexyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and four-dimensional computed tomography (4DCT) based-tumor volumes is unclear. This prospective study was conducted to determine the optimal threshold of PET/CT for gross tumor volume (GTV) delineation using 4DCT as the standard reference for locally advanced lung cancer patients.Material and Methods: Ten patients with histologically proven primary lung cancer who underwent radiotherapy fromJune 2017 to March 2018 in Ramathibodi Hospital were enrolled in the study. The 4DCT simulation and 18F-FDG PET/CT simulation were performed on the same position and same date. Eight standard uptake value (SUV) thresholds of SUV 1.5.0-2.0 and 15.0-35.0% of maximum SUV were selected for contouring in order to be compared with 4DCT based tumor volumes. The comparison methods used were the mean percentage volume change, dice similarity coefficient (DSC), and 3D-centroid shift of the targets between 18F-FDG PET/CT-based gross tumor volume (GTVPET) and internal gross tumor volume (IGTV) from 4DCT.Results: The largest and smallest volume of primary tumors were 422.6 cm3 and 5.9 cm3. GTVPET contoured using SUV 1.5 (GTVPET1.5) approximated closely to IGTV in all the parameters, including volume change, DSC, and 3D-centroid shift. The best median percentage volume change, median DSC, and median centroid shift between IGTV and GTVPET1.5 were 5.55, 0.745 and 0.37, respectively.Conclusion: GTVPET contoured by 18F-FDG PET at SUV1.5 corresponded most closely to the IGTV in all parameters. Further study with a larger sample size and clinical outcome analysis is needed.

scholarly journals Molecular imaging and immunotherapy

2020 ◽  
Vol 35 (1_suppl) ◽  
pp. 37-41
Author(s):  
Laura Evangelista
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Positron Emission Tomography ◽  
Clinical Practice ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

The utility of positron emission tomography (PET) for the evaluation of response to immunotherapy has been considered a hot topic, particularly in the last 2 to 3 years. Different experiences have been collected in clinical practice, with 18F-Fluorodeoxyglucose (FDG) PET/computed tomography (CT), particularly in patients affected by lymphoma, malignant melanoma, and lung cancer. It has been tested in different settings of disease, from the prediction to the prognosis relative to the response to immunotherapy. In the present mini-review, some evidence is reported about the role of FDG PET/CT in patient candidates to or treated with immunotherapy.

scholarly journals Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma

2020 ◽  
Vol 21 (15) ◽  
pp. 5406 ◽  
Author(s):  
Bastien Jamet ◽  
Elena Zamagni ◽  
Cristina Nanni ◽  
Clément Bailly ◽  
Thomas Carlier ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Residual Disease ◽  
Complete Response ◽  
Therapeutic Assessment ◽  
Complete Metabolic Response ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Minimal Residual

Serum markers and bone marrow examination are commonly used for monitoring therapy response in multiple myeloma (MM), but this fails to identify minimal residual disease (MRD), which frequently persists after therapy even in complete response patients, and extra-medullary disease escape. Positron emission tomography with computed tomography using 18F-deoxyglucose (FDG-PET/CT) is the reference imaging technique for therapeutic assessment and MRD detection in MM. To date, all large prospective cohort studies of transplant-eligible newly diagnosed MM patients have shown a strong and independent pejorative prognostic impact of not obtaining complete metabolic response by FDG-PET/CT after therapy, especially before maintenance. The FDG-PET/CT and MRD (evaluated by flow cytometry or next-generation sequencing at 10−5 and 10−6 levels, respectively) results are complementary for MRD detection outside and inside the bone marrow. For patients with at least a complete response, to reach double negativity (FDG-PET/CT and MRD) is a predictive surrogate for patient outcome. Homogenization of FDG-PET/CT interpretation after therapy, especially clarification of complete metabolic response definition, is currently underway. FDG-PET/CT does not allow MRD to be evaluated when it is negative at initial workup of symptomatic MM. New PET tracers such as CXCR4 ligands have shown high diagnostic value and could replace FDG in this setting. New sensitive functional magnetic resonance imaging (MRI) techniques such as diffusion-weighted MRI appear to be complementary to FDG-PET/CT for imaging MRD detection. The goal of this review is to examine the feasibility of functional imaging, especially FDG-PET/CT, for therapeutic assessment and MRD detection in MM.

scholarly journals 18 F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose

2012 ◽  
Vol 7 (1) ◽  
pp. 106 ◽  
Author(s):  
Mariangela Massaccesi ◽  
Maria Calcagni ◽  
Maria Spitilli ◽  
Fabrizio Cocciolillo ◽  
Francesca Pelligrò ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Dose ◽  
Small Cell Lung Cancer ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Early Metabolic Response
Sign in / Sign up

Export Citation Format

Share Document